
Corifact Market Industry Forecast Improves Driven by Increasing Global Demand

The Business Research Company's Corifact Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035



Corifact Market

The Business Research Company

LONDON, GREATER LONDON, UNITED KINGDOM, November 2, 2026 /EINPresswire.com/ -- "The Corifact market is experiencing significant attention due to its crucial role in managing bleeding disorders and surgical bleeding. As medical advancements and demographic changes continue to evolve, the demand for effective fibrinogen concentrates like Corifact is set to rise. Let's explore the current market size, key growth factors, regional outlook, and major trends shaping this important healthcare segment.

Current Size and Growth Outlook of the Corifact Market

The expansion seen in the Corifact market during the past years can be linked to better recognition of fibrinogen deficiency, improvements in trauma care, enhanced surgical bleeding management protocols, approvals for plasma-derived therapies, and increased hospital adoption. Looking ahead, growth is expected to be driven by a rise in emergency surgeries, the needs of an aging population, expanding trauma centers, improved coagulation diagnostic methods, and a growing demand for quick-acting hemostatic agents. Key trends likely to influence the market include greater usage of fibrinogen concentrates, a focus on rapid bleeding control, expansion in trauma and surgical care, increased hospital-based hemostasis management, and wider adoption in treating liver disease.

Download a free sample of the corifact market report:
https://thebusinessresearchcompany.com/sample_request?id=98548660&type=smp&name=Corifact%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR

Understanding Corifact and Its Medical Importance
Corifact is a fibrinogen concentrate used primarily to control bleeding in patients with low fibrinogen levels or fibrinogen deficiency, conditions often seen in trauma, surgical procedures, and liver disease. By supplying fibrinogen, a vital protein for blood clot formation, Corifact supports the body's natural clotting mechanism and helps prevent excessive bleeding, making it an essential treatment option in critical care settings.

Rising Prevalence of Bleeding Disorders as a Growth Catalyst
One of the main factors propelling the Corifact market is the increasing rate of bleeding disorders worldwide. These conditions hinder the blood's ability to clot properly, leading to prolonged or excessive bleeding. The rise in these disorders is linked to improved diagnostic capabilities, enhanced awareness, advancements in genetic testing, changing lifestyles, and the presence of underlying health conditions. Corifact addresses bleeding issues caused by factor XIII deficiency by replacing the missing clotting factor, thereby promoting stable blood clot formation and reducing bleeding complications. For example, a UK report from December 2023 by the United Kingdom Haemophilia Centre Doctors' Organisation documented thousands of patients living with haemophilia A and B and related clotting factor deficiencies, highlighting a clear demand for effective treatments like Corifact.

View the full corifact market report:
https://thebusinessresearchcompany.com/report/corifact-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR

Impact of Growing Demand for Biological Products on the Corifact Market
Another important driver of the Corifact market is the rising demand for biological products—complex pharmaceuticals derived from living organisms used to diagnose, prevent, and treat various diseases. This increase is fueled by environmental concerns, greater consumer awareness, and the need for sustainable, effective alternatives to synthetic drugs. Corifact supports the biological product sector by enhancing product stability, bioavailability, and efficacy through innovative formulation and delivery methods. For instance, a 2025 report by the US Assistant Secretary for Planning and Evaluation detailed how biosimilar revenues vary greatly but also highlighted regulatory changes that could lower development costs and boost lifetime revenues significantly, reinforcing the market's growth potential.

Surge in Surgical Procedures Driving Corifact Market Expansion
The growing number of surgical interventions is also a vital factor in the Corifact market's growth. Surgical procedures, performed to treat injuries, diseases, or abnormalities, are increasing due to an aging global population and advances in minimally invasive techniques that

make surgery safer and more accessible. Corifact plays a key role in surgeries by preventing excessive bleeding in patients with congenital factor XIII deficiency, aiding clot stability and wound healing. For example, data from the American Society of Plastic Surgeons in June 2024 showed that minimally invasive procedures grew by 7 percent in 2023, outpacing traditional surgery growth and reflecting a higher demand for supportive treatments like Corifact.

Fastest Growing Regions in the Corifact Market
In 2025, North America held the largest share of the global Corifact market. However, the Asia-Pacific region is predicted to experience the fastest growth over the coming years. The market analysis includes regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa, providing a comprehensive global perspective on growth opportunities.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company"

Oliver Guirdham
The Business Research Company
+ +44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

This press release can be viewed online at: https://www.einpresswire.com/article/952804203

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.